Literature DB >> 16210493

Immunogenicity of meningococcal ACYW135 polysaccharide vaccine in Saudi children 5 to 9 years of age.

M Khalil1, Y Al-Mazrou, P Balmer, J Bramwell, N Andrews, R Borrow.   

Abstract

Meningococcal tetravalent polysaccharide vaccines were observed to be immunogenic in Saudi children 5 to 9 years of age, with >90% having serum bactericidal antibody titers of > or = 8 for serogroups A, Y, and W135; for serogroup C, 77% were putatively protected after vaccination.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16210493      PMCID： PMC1247841          DOI： 10.1128/CDLI.12.10.1251-1253.2005

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN： 1071-412X


  13 in total

1.  Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination.

Authors:  Martin C J Maiden; James M Stuart
Journal:  Lancet       Date:  2002-05-25       Impact factor: 79.321

2.  Enteric bacteria cross-reactive with Neisseria meningitidis groups A and C and Diplococcus pneumoniae types I and 3.

Authors:  J B Robbins; L Myerowitz; J K Whisnant; M Argaman; R Schneerson; Z T Handzel; E C Gotschlich
Journal:  Infect Immun       Date:  1972-11       Impact factor: 3.441

3.  Serologic responses to ACYW135 polysaccharide meningococcal vaccine in Saudi children under 5 years of age.

Authors:  Y Al-Mazrou; M Khalil; R Borrow; P Balmer; J Bramwell; G Lal; N Andrews; M Al-Jeffri
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

4.  Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants.

Authors:  R Gold; M L Lepow; I Goldschneider; T L Draper; E C Gotschlich
Journal:  J Clin Invest       Date:  1975-12       Impact factor: 14.808

5.  Changes in epidemiological pattern of Meningococcal disease in Saudi Arabia. Does it constitute a new challenge for prevention and control?

Authors:  Yagob Y Al-Mazrou; Mohamed H Al-Jeffri; Mohamed N Abdalla; Sirag A Elgizouli; Amin A Mishskas
Journal:  Saudi Med J       Date:  2004-10       Impact factor: 1.484

6.  Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age.

Authors:  H Peltola; H Mäkelä; H Käyhty; H Jousimies; E Herva; K Hällström; A Sivonen; O V Renkonen; O Pettay; V Karanko; P Ahvonen; S Sarna
Journal:  N Engl J Med       Date:  1977-09-29       Impact factor: 91.245

7.  Disease burden and case management of bacterial meningitis among children under 5 years of age in Saudi Arabia.

Authors:  Yagob Y Al-Mazrou; Elgeili K Musa; Mohamed N Abdalla; Mohamed H Al-Jeffri; Sami H Al-Hajjar; Omer M Mohamed
Journal:  Saudi Med J       Date:  2003-12       Impact factor: 1.484

8.  Development and evaluation of a tetraplex flow cytometric assay for quantitation of serum antibodies to Neisseria meningitidis serogroups A, C, Y, and W-135.

Authors:  Gouri Lal; Paul Balmer; Helen Joseph; Maureen Dawson; Ray Borrow
Journal:  Clin Diagn Lab Immunol       Date:  2004-03

9.  Serum antibodies to capsular polysaccharide vaccine of group A Neissera meningitidis followed for three years in infants and children.

Authors:  H Käyhty; V Karanko; H Peltola; S Sarna; P H Mäkelä
Journal:  J Infect Dis       Date:  1980-12       Impact factor: 5.226

10.  Escherichia coli K51 and K93 capsular polysaccharides are crossreactive with the group A capsular polysaccharide of Neisseria meningitidis. Immunochemical, biological, and epidemiological studies.

Authors:  N Guirguis; R Schneerson; A Bax; W Egan; J B Robbins; J Shiloach; I Orskov; F Orskov; A el Kholy
Journal:  J Exp Med       Date:  1985-12-01       Impact factor: 14.307
View more
  4 in total

1.  Immunogenicity and safety of a meningococcal quadrivalent conjugate vaccine in Saudi Arabian adolescents previously vaccinated with one dose of bivalent and quadrivalent meningococcal polysaccharide vaccines: a phase III, controlled, randomized, and modified blind-observer study.

Authors:  Yagob Al-Mazrou; Mohamed Khalil; Helen Findlow; Helen Chadha; Valerie Bosch Castells; David R Johnson; Ray Borrow
Journal:  Clin Vaccine Immunol       Date:  2012-05-02

2.  Serum antibody responses in Ethiopian meningitis patients infected with Neisseria meningitidis serogroup A sequence type 7.

Authors:  Gunnstein Norheim; Abraham Aseffa; Mohammed Ahmed Yassin; Getahun Mengistu; Afework Kassu; Dereje Fikremariam; Wegene Tamire; Yared Merid; E Arne Høiby; Dominique A Caugant; Elisabeth Fritzsønn; Torill Tangen; Tsegaye Alebel; Degu Berhanu; Morten Harboe; Einar Rosenqvist
Journal:  Clin Vaccine Immunol       Date:  2007-02-14

3.  Safety and immunogenicity of a meningococcal quadrivalent conjugate vaccine in five- to eight-year-old Saudi Arabian children previously vaccinated with two doses of a meningococcal quadrivalent polysaccharide vaccine.

Authors:  Mohamed Khalil; Yagob Al-Mazrou; Helen Findlow; Helen Chadha; Valerie Bosch Castells; David R Johnson; Ray Borrow
Journal:  Clin Vaccine Immunol       Date:  2012-08-01

Review 4.  An evaluation of emerging vaccines for childhood meningococcal disease.

Authors:  Debajeet Choudhuri; Tanvir Huda; Evropi Theodoratou; Harish Nair; Lina Zgaga; Rachel Falconer; Ivana Luksic; Hope L Johnson; Jian Shayne F Zhang; Shams El Arifeen; Christopher B Nelson; Ray Borrow; Harry Campbell; Igor Rudan
Journal:  BMC Public Health       Date:  2011-04-13       Impact factor: 3.295
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.